Investors
The opportunity
We are building an integrated biotechnology and AI company in Saudi Arabia, with Chromatica as our first software product.
Where we are
- Founder-funded to date
- Chromatica at MVP stage and preparing for pilot deployment
- Early-adopter testing has taken place
- Genetic prediction model at research prototype stage
- Preliminary experimental results reported in protein and enzyme R&D
- Registered Saudi entity
Funding target
USD 500,000–1,000,000
We are seeking angel investors, strategic investors, biotech and healthtech funds, and R&D and industrial partners.
Market
Saudi market estimates
| Area | Estimated Saudi market | 2% share target |
|---|---|---|
| Proteins | SAR 13 billion | SAR 260 million |
| Genomic and disease data analysis | SAR 500 million | SAR 10 million |
| Chromosome analysis | SAR 150 million | SAR 3 million |
Company estimates, not official statistics. Sufficient published data on the Saudi market alone is not available, so these figures come from a conservative analysis of global data, estimated local demand, service prices and usage volumes. The share target is an ambition, not a forecast or a result.
Use of funds
Where investment would go
- Chromatica development
- AI and bioinformatics capacity
- Protein and enzyme research
- Lab equipment and consumables
- GPU and cloud computing
- Hiring scientists and engineers
- Validation and regulatory preparation
- Saudi market entry
Request the investor deck
Tell us about yourself and we will send the deck.
This page is for information only. It is not an offer of securities or investment advice.